Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Change in Cash (2016 - 2025)

Haemonetics has reported Change in Cash over the past 17 years, most recently at $66.9 million for Q4 2025.

  • Quarterly results put Change in Cash at $66.9 million for Q4 2025, up 210.44% from a year ago — trailing twelve months through Dec 2025 was $42.5 million (down 66.48% YoY), and the annual figure for FY2025 was $128.0 million, up 221.1%.
  • Change in Cash for Q4 2025 was $66.9 million at Haemonetics, up from $3.5 million in the prior quarter.
  • Over the last five years, Change in Cash for HAE hit a ceiling of $165.6 million in Q2 2024 and a floor of -$157.0 million in Q4 2023.
  • Median Change in Cash over the past 5 years was $3.4 million (2021), compared with a mean of $8.7 million.
  • Biggest five-year swings in Change in Cash: crashed 813.05% in 2023 and later skyrocketed 13118.6% in 2024.
  • Haemonetics' Change in Cash stood at $19.0 million in 2021, then plummeted by 190.72% to -$17.2 million in 2022, then crashed by 813.05% to -$157.0 million in 2023, then soared by 113.73% to $21.6 million in 2024, then skyrocketed by 210.44% to $66.9 million in 2025.
  • The last three reported values for Change in Cash were $66.9 million (Q4 2025), $3.5 million (Q3 2025), and -$13.9 million (Q2 2025) per Business Quant data.